Form 4: Mirum Pharmaceuticals Executive Peter Radovich Reports Stock Transactions

Peter Radovich, President and COO of Mirum Pharmaceuticals, reports the vesting of performance restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• On March 15, 2025, Peter Radovich, President and COO of Mirum Pharmaceuticals, vested 14,440 performance restricted stock units, each representing a contingent right to receive one share of Mirum's common stock.
• Following the vesting, Radovich sold 7,879 shares of common stock on March 17, 2025, at a price of $44.2143 per share.
• The sale was conducted to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
• After these transactions, Radovich directly owns 18,672 shares of Mirum Pharmaceuticals common stock and 7,220 performance restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the change in ownership, but it is unlikely to be significant.

Key Dates